Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT05277129
Recruiting Observational

The Immune Response to Stroke

NCT05277129 · tracked via the Priya Life Science Norway tracker
Sponsor
University of Oslo
Phase
Observational
Started
2021-06-24
Last updated
2022-03-14

Condition(s) studied

Stroke, AcuteDementia

Investigational drug(s) / intervention(s)

Analysis of post-stroke immune responses

Analysis of post-stroke immune responses: Analysis of immune responses in peripheral blood

Study summary

Some patients develop cognitive decline after a stroke, but we don't always understand the mechanisms. It has been proposed that a proportion of the patients develop an autoimmune immune response, and that this could potentially explain the cognitive decline in some of the patients. The current study aims to investigate this hypothesis in a subgroup of patients with stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Stroke \< 72 h * Age \> 18 years Exclusion Criteria: * Brain hemorrhage verified by CT or MRI scan * Previous or present immunological disease or other serious comorbidity * Ongoing immune respons after infection or vaccination \< 1 month * Cognitive without ability to understand and/or give an informed consent to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Akershus University Hospital Lørenskog Norway Recruiting

More University of Oslo trials in Norway

Norwegian Tuning in to Kids Effectivity Study Active, not recruiting
SPiT-frequency II_Peri-implantitis Starting soon
B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. Recruiting
Advanced Care Planning for the Severely Ill Home-dwelling Elderly Recruiting
A Study of School Absenteeism and Student Well-being in Elementary Schools Enrolling by invitation

Other trials for the same condition

Multimodal Assesment of Alzheimer Patients Recruiting
B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. Recruiting
The Akershus Study of Ischemic Stroke and Thrombolysis -1 Recruiting
Virtual Nature as a Health-promoting Intervention for Nursing Home Residents With Dementia Active, not recruiting
Decoding Death and Dying in People With Dementia by Digital Thanotyping Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05277129 on ClinicalTrials.gov ↗ ← All trials in Norway